Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | GRIN2B | Q13224 | 9/20 | 0.50 |
| ▸ | JAK2 | O60674 | 4/20 | 0.49 |
| ▸ | JAK1 | P23458 | 4/20 | 0.49 |
| ▸ | TYK2 | P29597 | 3/20 | 0.49 |
| ▸ | JAK3 | P52333 | 2/20 | 0.49 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL204659 | 0.82 | HPGDS (0.48) | SMN1; SMN2NPC1RAB9ACYP2C19GRIN2B | |
| SCHEMBL2708081 | 0.82 | HPGDS (0.48) | SMN1; SMN2NPC1RAB9ACYP2C19GRIN2B | |
| SCHEMBL27035789 | 0.78 | SMN1; SMN2 (0.58) | SMN1; SMN2NPC1RAB9ACYP2C19GRIN2B | |
| SCHEMBL25291831 | 0.77 | SMN1; SMN2 (0.57) | SMN1; SMN2NPC1RAB9ACYP2C19GRIN2B | |
| SCHEMBL2307512 | 0.76 | GRIN2B (0.72) | SMN1; SMN2NPC1RAB9ACYP2C19GRIN2B | |
| SCHEMBL1992659 | 0.76 | SMN1; SMN2 (0.58) | SMN1; SMN2NPC1RAB9ACYP2C19GRIN2B | |
| SCHEMBL4035554 | 0.75 | SMN1; SMN2 (0.72) | SMN1; SMN2NPC1RAB9ACYP2C19GRIN2B | |
| SCHEMBL29101238 | 0.74 | SMN1; SMN2 (0.54) | SMN1; SMN2NPC1RAB9ACYP2C19GRIN2B | |
| SCHEMBL1352250 | 0.74 | SMN1; SMN2 (0.60) | SMN1; SMN2NPC1RAB9ACYP2C19GRIN2B | |
| SCHEMBL987875 | 0.74 | GRIN2B (0.50) | SMN1; SMN2NPC1RAB9ACYP2C19GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170029408-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2017-02-02 | — | — | US | disclosed |
| US-9511056-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2016-12-06 | — | — | US | disclosed |
| US-8841278-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2014-09-23 | — | — | US | disclosed |
| US-20140249074-A1 | ANTIVIRAL COMPOUNDS | GILEAD PHARMASSET LLC (US) | 2014-09-04 | — | — | US | disclosed |
| US-8822430-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2014-09-02 | — | — | US | disclosed |
| US-8669234-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2014-03-11 | — | — | US | disclosed |
| US-20140051656-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2014-02-20 | — | — | US | disclosed |
| US-20140039021-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2014-02-06 | — | — | US | disclosed |
| US-8575118-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2013-11-05 | — | — | US | disclosed |
| US-20130137877-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-05-30 | — | — | US | disclosed |
| US-20120264711-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2012-10-18 | — | — | US | disclosed |
| US-20120157404-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140051656-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | SMN1; SMN2 1564/4885NPC1 516/4885RAB9A 1694/4885 |
| US-20170029408-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | SMN1; SMN2 1564/4885NPC1 516/4885RAB9A 1694/4885 |
| US-20130137877-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | SMN1; SMN2 1564/4885NPC1 516/4885RAB9A 1694/4885 |
| US-20120264711-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | SMN1; SMN2 1564/4885NPC1 516/4885RAB9A 1694/4885 |
| US-20120157404-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | SMN1; SMN2 1564/4885NPC1 516/4885RAB9A 1694/4885 |
| US-20140039021-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | SMN1; SMN2 1564/4885NPC1 516/4885RAB9A 1694/4885 |
| US-20140249074-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | SMN1; SMN2 1564/4885NPC1 516/4885RAB9A 1694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.